February 1, 2022
Ono Pharmaceutical saw its revenue surge more than 15% in April-December on the back of brisk sales performances from its PD-1 inhibitor Opdivo (nivolumab) and SGLT2 inhibitor Forxiga (dapagliflozin). Operating profit leveled off, however, due to a settlement payout tied...read more